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Abstract
Background: Although Group A beta hemolytic streptococcus (GABHS) can cause bacterial pharyngitis, the most
common etiology is viral; despite this viral etiology, antibiotics are commonly prescribed for this infection in
industrialized countries. We investigated the prevalence of GABHS in adult pharyngitis patients from lower
socioeconomic settings in Karachi, Pakistan, how often antibiotics are prescribed for pharyngitis and if appropriate
agents were used in a developing world setting. Finally, we wanted to see the usefulness of modified McIsaac
scores in predicting positive cultures.
Methods: Adult patients were recruited from three local hospital outpatient dispensaries (OPDs). All patients aged
14–65 years who were suspected of having bacterial pharyngitis had throat swabs taken. Laboratory results for
GABHS pharyngitis were then compared with their prescriptions. Appropriateness (using the World Health
Organization’s definition) and type of antibiotic prescribed were assessed.
Results: Of 137 patients, 30 patients each were studied for scores of 0, 1, 2 and 3; 17 patients were studied for
score 4. Although 6 (4.4%) patients were GABHS+, for a prevalence of 43.8 per 1000 population, antibiotics were
prescribed to 135 patients (98.5%). Of these, only 11.1% received appropriate antibiotics while 88.9% received
inappropriate antibiotics. Penicillins were prescribed most (34.1%), especially amoxicillin/clavulanate; followed by
macrolides (31.1%), especially the second-generation agents, and fluoroquinolones (14.8%). McIsaac scores were
found to be 100% sensitive and 68.7% specific, giving a positive predictive value (PPV) of 12.7% and a negative
predictive value (NPV) of 100%.
Conclusions: Antibiotics were prescribed irrationally to adult pharyngitis patients, as most cultures were negative
for bacterial infection. McIsaac modification of Centor scores related directly to culture results. We would therefore
highly recommend its use to help family physicians make treatment decisions for adult pharyngitis patients.
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Background
Group A beta hemolytic Streptococcus (GABHS) is com-
monly implicated in bacterial pharyngitis [1]. Starting
treatment with antibiotics for GABHS infection, within
the first 24–48 hours of illness, when a bacterial cause is
highly suspected, has been found to decrease duration of
symptoms, such as sore throat, fever and adenopathy by
approximately one day [2], and prevent complications of
GABHS pharyngitis, particularly rheumatic fever and
rheumatic heart disease [3]. However, the majority of
pharyngitis cases in adults are of viral etiology [4]; only
5–15% of cases suffer from bacterial pathogens that re-
quire prompt antibiotic treatment [5,6].
The World Health Organization (WHO) defines an
appropriate prescription as “administration of the right
drug indicated for the disease, in the right dose, through
an appropriate route of administration, for the right dur-
ation” [7]. When these criteria are not fulfilled, the pre-
scription is considered inappropriate. Inappropriate
antibiotic prescriptions for treatment of pharyngitis have
contributed to the emergence of resistant strains of oro-
pharyngeal human flora [8] which in turn, have
increased morbidity, mortality, and health-care costs [9].
Approximately three quarters of pharyngitis patients
have received inappropriate antibiotic prescriptions, by
receiving antibiotics for viral infections or otherwise not
adhering to the WHO definition [10-12].
First-line agents for treatment of bacterial pharyngitis
include penicillin, ampicillin or amoxicillin.13 Alternative
options include erythromycin (especially in patients with
a non-life-threatening allergy to penicillin) and first-
generation cephalosporins (CG) [1]. Both erythromycin
and cephalosporins are also considered reasonable alter-
natives to penicillin in patients who fail to respond to
penicillin or continue to become re-infected following
penicillin therapy [13-15]. As GABHS is the most im-
portant pathogen causing infection, fluoroquinolones,
and sulfamethoxazole/trimethoprim that do not cover
Gram-positive pathogens very well are not recom-
mended. Although amoxicillin-clavulanate, clarithromy-
cin, azithromycin and second-generation cephalosporins
work very well against GABHS infection, they are con-
sidered third-line alternatives due to their broader
spectrum of action and potential for causing resistance.
Throat swab and culture is the gold standard for diag-
nosis of pharyngitis. A rapid antigen detection test
(RADT) can also give relatively specific diagnosis in a
physician’s office. Although a WHO technical report
states that there is less possibility of false-positive results
with RADT, RADT kits vary in sensitivity, which ranges
from 31–95%. Therefore, RADT cannot be substituted
for standard blood agar cultures [3]. Because antibiotics
treatment should occur fairly promptly, diagnosis of
pharyngitis is often based on clinical symptoms; throat
swabs are not always taken [16]. Thus to improve the
diagnostic criteria, several scoring systems have been
developed to predict, on a clinical basis, whether
patients have bacterial or viral pharyngitis [17,18].
Among the many devised clinical scores, the Centor
criteria are reliable predictors of GABHS pharyngitis.
They include evaluating patients for tonsillar exudates,
tender anterior cervical lymphadenopathy or lymph-
adenitis, absence of cough, and history of fever (oral
temperature greater than 38.3°C; 101°F) [19]. More re-
cently, the Centor score was modified by incorporating
patient's age, which allows the physician to place
patients in low-, moderate-, or high-risk groups. The use
of the McIsaac Modified Centor score has helped in de-
creasing inappropriate antibiotic use by almost 88% [18].
Several guidelines have been published on diagnosis
and treatment of streptococcal pharyngitis in adults;
however, not all are in agreement. The American College
of Physicians’ (ACP) guideline endorsed by Centre for
Disease Control (CDC), American Academy of Family
Physicians and the American Society of Internal Medi-
cine, recommend that patients with low Centor scores of
0 or 1 (i.e., low risk for streptococcal pharyngitis) do not
require any testing or treatment with antibiotics. For
patients with Centor scores of 2 or, 3, the guidelines sug-
gest using a RADT, which would give a sensitivity of >
80% for accurate diagnosis of GABHS infection, and pre-
scribing antibiotics to patients with positive tests [20,21].
Empirical treatment with antibiotics is recommended
for patients with Centor scores of 3 or 4 [22]. However,
practice guidelines issued by the American Heart Asso-
ciation [23], American Academy of Pediatrics [24], and
Infectious Diseases Society of America (IDSA) [25] rec-
ommend microbiologic confirmation by throat culture
or RADT to diagnose all adults with pharyngitis prior
to antibiotic prescribing, regardless of their Centor
scores. IDSA and others are of the opinion that if pres-
tigious organizations like AAFP and CDC endorse the
option of not culturing at all for any given score, it
would be unlikely that physicians would opt for either
RADT or culture [26].
These concerns were addressed by McIsaac who
pointed out that missed infections are not due solely to
score approaches, as physicians do not obtain a throat
swab for every case of sore throat [27]. Therefore, treat-
ment decisions based on clinical judgment would already
miss 50% of GABHS infections, while 20–40% of the lar-
ger number of non-GABHS sore throat presentations
would be identified as needing antibiotics [19,28].
Given the controversy in clinical guidelines and not
knowing how physicians in Pakistan generally treat their
adult pharyngitis patients, we investigated whether anti-
biotics are prescribed appropriately for primary treat-
ment of pharyngitis within a developing world setting
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and under low socio-economic conditions. We also eval-
uated the sensitivity and specificity of McIsaac Modified
Centor scores in predicting GABHS pharyngitis in our
patient populations. Finally, we evaluated whether the
choice of antibiotic to treat pharyngitis was appropriate,
in terms of antibiotic class, dose, and duration of ther-
apy. Our study did not address use of antibiotics for sec-
ondary prevention of pharyngitis or asymptomatic
carrier state.
Methods
Study setting
The study was conducted in three tertiary care hospitals
—the Jamal Noor hospital, Zubaida Medical Centre and
the Civil Hospital, within two different areas of Karachi
(Dhoraji and Bander Road) where outpatient dispensar-
ies (OPD) were available. The clinical ethics committees
of all three hospitals gave their approval. Before starting
the study, educational sessions were set up at the clinics
to describe the study and consent process to clinic
nurses and physicians. Informed consent was obtained
from all study participants by the clinic physician.
Patient recruitment
All patients between the ages of 14 and 65 years of age,
suspected of having bacterial pharyngitis were asked to
participate in the study between March and October
2005. Patients who were younger than 14 years, im-
munocompromised (i.e., had autoimmune diseases in-
cluding HIV/AIDS or were on immunosuppressive
agents), or had been on antibiotics 24–48 hours before
were not included in the study.
Patients who agreed to participate were categorized
according to the McIsaac Modified Centor System into
scores 0, 1, 2, 3 and 4 [27]. One point was assigned to
each of the following symptoms: tonsillar exudates, ten-
der anterior cervical lymphadenopathy or lymphadenitis,
absence of cough, and history of fever (oral temperature
greater than 38.3°C; 101°F), and one point was deducted
if the patient was older than 45 years.
Microbiology
A throat swab was collected by the clinic physician using
a sterile swab from the posterior pharynx, tonsils and/or
inflamed areas. These swabs were transported to the
microbiological laboratory facility of Zubaida Medical
Center, which is an ISO 2001 certified laboratory and
follows the Monica Cheesbrough “District laboratory
practice in tropical countries” guidelines [29] for speci-
men testing, and the Clinical and Laboratory Standards
Institute (CLSI) guidelines [30] to perform the cultures.
Each specimen was cultured on a sheep blood agar
plate and a chocolate agar plate in anaerobic environ-
ment at 35°–37°C for 18–24 hours before reading for
GABHS, and then in CO2 rich atmosphere 35°C for 24
hours. A colony grown on blood agar plate and chocolate
agar was taken, and streaked on the nutrient agar plate.
A bacitracin disc, and penicillin, ampicillin, amoxicillin,
amoxicillin-clavulanate, cephradine, clarithromycin and
erythromycin, were then placed on the plate and were
incubated for 24 hours. Based on zones of inhibition,
they were graded as sensitive, intermediate or resistant.
Testing methodology was same for all patients.
Definitions
Inappropriate treatment was defined as per the WHO,
which suggests that administration of the right drug
indicated for the disease, in the right dose, through an
appropriate route of administration, for the right dur-
ation [6]. Thus, both infected (GABHS+) patients who
did not receive antibiotics, and uninfected (GABHS–)
patients who did receive antibiotic prescriptions were
considered to receive inappropriate treatment.
A second aspect of appropriate antibiotic prescription
was whether the choice of antibiotic for GABHS+ pha-
ryngitis was from a recommended class, in the right
dose and for the right duration. When evaluating a phy-
sician’s choice of antibiotics, we assumed that all
patients who received antibiotics were infected; prescrip-
tions were then considered appropriate if they pre-
scribed an accurate dose and duration of first-line agents
or second-line alternative agents. Prescriptions were
considered inappropriate if patients received inappropri-
ate doses or duration of first- or second-line agents, or
third- line agents or antibiotics that are not recom-
mended for pharyngitis infection.
First-line antibiotics included penicillin (oral penicillin
V 500 mg every 8 hours for 10 days; benzyl penicillin
0.6–1.2 million units IM once; oral ampicillin 500 mg
every 6 hours for 10 days; oral amoxicillin 500 mg every
8 hours for 10 days) [20]. Appropriate alternative
second-line agents included cephalexin (500 mg every
12 hours for 10 days) and other first-generation cepha-
losporins, cefaclor (500 mg every 8 hours orally for
10 days), a second-generation cephalosporin [31] and
erythromycin for penicillin-allergic patients (250 mg p.o.
every 6 hours or 500 mg every 12 or 6 hours for 10 days).
Third-line agents were considered inappropriate, because
they are too broad-spectrum, or do not have adequate
activity. Broad-spectrum agents included amoxicillin-
clavulanate (500–875 mg orally every 12 hours for
10 days), second-generation macrolides such as clarithro-
mycin (250 mg orally every 12 hours for 5 days), azithro-
mycin (500 mg orally on day 1; 250 mg on days 2–5 for
5 days) and roxithromycin (150 mg orally every 12 hours
or 300 mg once daily for 10 days), broader-spectrum sec-
ond-generation cephalosporins like cefuroxime (250 mg
or 500 mg every 12 hours for 5–10 days) and third-
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generation cephalosporins like cefixime (400 mg orally
daily for 5 days). Use of erythromycin for non-penicillin
allergic patients was also considered inappropriate. Fi-
nally, antibiotics not recommended for Gram-negative
pathogens were also considered to be inappropriate
or third-line agents; these included fluoroquinolones
(e.g., ciprofloxacin, levofloxacin and ofloxacin); sulfona-
mides such as sulfamethoxazole/trimethoprim and tetra-
cyclines (e.g., doxycycline, minocycline, tetracycline, and
oxytetracycline).
Study outcomes and statistics
The primary outcome was the prevalence of GABHS in-
fection in the adult pharyngitis patients from a low
socioeconomic setting. Secondary outcomes included 1)
number of prescriptions used for adult pharyngitis; 2)
appropriateness of prescribed antibiotics; and 3) diag-
nostic accuracy of the Modified Centor criteria.
By comparing patients’ culture results, we could deter-
mine the prevalence of infection. To determine whether
patients received appropriate or inappropriate prescrip-
tions, culture results were compared with antibiotic pre-
scriptions. Sensitivity, specificity, positive predictive and
negative predictive value of the McIsaac score approach
was determined by ratios of false positives, true posi-
tives, false negatives and true negatives.
Results
Table 1 shows the demographics of the study population.
Of the 137 patients, the average age of the study popula-
tion was 26 years old while the median age was 23 years.
There were more males than females who presented
with symptoms of pharyngitis (66% male vs 34%
females). Thirty patients each with scores 0, 1, 2 and 3,
and 17 patients with score 4 were evaluated for bacterial
pharyngitis (N= 137); of these patients, only 6 were
GABHS+ but 135 were treated with antibiotics. Thus,
the prevalence of bacterial pharyngitis in our population
was 43.8 per 1000 population. Penicillin was the most
frequently prescribed antibiotic class (34.1%). Within
this class, the majority of prescriptions were for
amoxicillin-clavulanate (26.6%), a broad-spectrum peni-
cillin. Approximately 15% of the prescriptions were for
cephalosporins (14.8%), with the third-generation cepha-
losporins accounting for 9.6% of the usage, second-
generation cephalosporins accounting for 3.7%, and
first-generation cephalosporins accounting for 1.4% of
total antibiotic usage. Macrolides (31.1%), quinolones
(14.8%), sulfonamide (3.0%), tetracyclines (2.2%) were
also prescribed for patients.
Antibiotics were prescribed inappropriately to adult
pharyngitis patients; we saw no association between anti-
biotic use and culture confirmation results (P = 0.75).
When cross tabulated, of the patients who were given
antibiotics, only 4% patients were GABHS+; 96% of
patients were GABHS– (Table 2).
A total of 135 patients received antibiotics, but only
15/135 (11.1%) received appropriate antibiotics; 120/
135 (88.9%) who received inappropriate antibiotics, not
recommended by current guidelines. Table 3 shows the
breakdown of the antibiotics received by the patients.
Only 8/135 (5.8%) of the patients received first-line
agents for treatment of pharyngitis; most patients
received second-line agents (7/135; 5.2%) and third-line
agents (120/135; 88.9%). Of the inappropriate antibio-
tics prescribed, macrolides (42/135; 31.1%) were pre-
scribed most, including erythromycin for non-penicillin
allergic patients, clarithromycin and roxithromycin;
followed by broad-spectrum penicillin; amoxicillin-
clavulanate (36/135; 26.7%), the third-generation ceph-
alosporin cefixime (13/135; 9.6%) and fluoroquinolones
(20/135; 14.8%).
Antibiotics were prescribed by brand names to 96.2%
of patients. Irrespective of which class of antibiotic was
prescribed, only 45% (61/135) of patients were pre-
scribed antibiotics at appropriate doses and durations,
whereas 55% (74/135) received prescriptions for in-
appropriate doses and/or durations.
Table 4 shows an even distribution of patients in each
of the 4 score groups (30 in each group), except for
group 4 (17 patients). The McIsaac score system was
found to be 100% sensitive and 68.7% specific, giving a
Table 1 Patient demographics
Variables N (%)
Total number of patients in study 137
Males, N (%) 91 (66.4%)
Females, N (%) 46 (33.5%)
Mean age ± SD 26 ± 10.71
Median age ± SD 23 ± 10.71
Antibiotics prescribed by physicians
Penicillin 46 (34.1%)
Macrolides 42 (31.1%)
Cephalosporins 20 (14.8%)
Quinolones 20 (14.8%)
Sulfonamide/Trimethoprim 4 (3.0%)
Tetracyclines 3 (2.2%)
Table 2 Appropriateness of antibiotic prescribing when
compared to culture results
Culture from
throat swab
Antibiotic prescribed Total
Yes No
Positive, N (%) 6 0 6 (4.4%)
Negative, N (%) 129 2 131 (95.6%)
Total, N (%) 135 2 137 (100%)
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positive predictive value (PPV) of 12.7% and a negative
predictive value (NPV) of 100%.
Discussion
This is the first study to look at appropriate antibiotic
use for adult pharyngitis in a developing world setting.
Our study showed that much antibiotic use is
unnecessary for patients who have pharyngitis—probably
because most such patients have viral, rather than bac-
terial, infections. In fact, only 4.3% of the patients in our
sample were found to be GABHS+; the rest were likely
viral infections.
Furthermore, even when antibiotics are used, physi-
cians are prescribing broader class agents for treatment,
Table 3 Antibiotics prescribed by physicians for adult pharyngitis patients
APPROPRIATE ANTIBIOTICS
Class Name Numbers (%)
Appropriate first-line agents
Penicillin Ampicillin 3 (2.2%)
Amoxicillin 5 (3.7%)
Total 8 (5.8%)
Appropriate alternative second-line agents
First-generation cephalosporins Cefadroxil 1 (0.7%)
Cephradine 1 (0.7%)
Second-generation cephalosporins Cefaclor 5 (3.7%)
Total 7 (5.2%)
NON-RECOMMENDED ANTIBIOTICS
Inappropriate or third-line agents
Broad spectrum penicillins Amoxicillin-Clavulanate 36 (26.7%)
Ampicillin-Cloxacillin 2 (1.5%)
Macrolides Erythromycin for patients not reported with penicillin allergy 14 (10.5%)
Clarithromycin 27 (20.0%)
Roxithromycin 1 (0.7%)
Third-generation cephalosporins Cefixime 13 (9.6%)
Quinolones Ciprofloxacin 2 (1.5%)
Levofloxacin 18 (13.3%)
Sulfonamides Sulfamethoxazole/trimethoprim 4 (3.0%)
Tetracyclines Oxytetracycline 3 (2.2)
Total 120 (88.9%)
Table 4 Cross tabulation of McIsaac modification of Centor score and culture
McIsaac modification of Centor score Culture positivity (N = 137) Total TN3 TP3 FP3
Score 0 0 (0%) 30 (100%) 30 30 – 0
Score 1 0 (0%) 30 (100%) 30 30 – 0
Score 2 0 (0%) 30 (100%) 30 30 – 0
Score 3 1 (3.4%) 29 (96.6%) 30 0 1 29
Score 4 5 (29.4%) 12 (70.6%) 17 0 5 12
Sensitivity4 100% (95% CI: 0.5–1)
Specificity4 68.7% (95% CI: 0.54–0.7)
PPV3,1 12.7% (95% CI: 0.05–0.26)
NPV3,2 100% (95% CI: 0.9–1)
1 Yes = Number of patients GABHS+ in culture / Total number of patients with respective score.
2 No = Number of patients not found GABHS+ in culture.
3 TN = True negative; TP = True positive; FP = False positive; PPV = positive predictive value; NPV = negative predictive value.
4 Sensitivity and specificity of scores 0 to 4.
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such as amoxicillin/clavulanate or macrolides, rather
than using the simple narrow-spectrum agents such as
penicillin or amoxicillin/ampicillin; even when the anti-
biotic choice was appropriate, doses and durations of
those antibiotics mostly were not. Although benzathine
penicillin is recommended by the WHO, we did not see
its usage in our study. Our investigation did not interro-
gate physicians’ motives; however, we speculate that they
preferred the ease and lower cost of oral antibiotics to
benzathine penicillin, which costs more and requires
intramuscular injection.
Although our findings are similar to those of other
studies conducted in western countries, the enormity of
the problem seems to be much larger in Pakistan due to
the large numbers of patients seeking medical attention
for pharyngitis [32,33]. Many factors could have contrib-
uted to inappropriate prescribing of antibiotics for pha-
ryngitis. Quality of health care is constrained by costs in
developing countries like Pakistan. Therefore, for a com-
mon ailment like sore throat, a costly throat swab and
culture is not a routine practice. Furthermore, RADT is
not an option in our setting because of its unavailability
and high cost. Finally, patients generally expect to get
the maximum benefit from a physician visit so that they
do not have to pay the cost of the next visit. As a result,
physicians are burdened with patients’ expectation of
providing all care during the patient’s first and only visit.
The results of our study would be generalizable to other
low income countries such as India, Afghanistan and
Bangladesh.
Our study showed that it would be useful for clinicians
in Pakistan to use the McIsaac Modified Centor score as
it is not costly, and is sensitive and specific enough to
reduce unnecessary antibiotic prescriptions. Based on
our study, we recommend that the score-only approach
would save antibiotics prescriptions for most patients, as
most adult patients with pharyngitis had scores of 0, 1
or 2. Although without a RADT test option, more anti-
biotics would be prescribed for patients with a score of 3
or 4, this percentage is better than the percentage of
patients getting inappropriate antibiotics without clinical
score-based screening at all. This modified Centor clin-
ical prediction rule holds more importance in our set-
ting because RADT is not widely available in our
country; given their high cost and varied sensitivity
(31–95%) of the different RADT kits, their use will be
limited [3]. During the course of our study, we saw
that affordability of RADT testing was the major con-
cern in this setting, which resulted in almost 99% of
patients being prescribed antibiotics. Following a score
approach would significantly reduce unnecessary anti-
biotics prescriptions.
Our study implies that, as with developed countries,
clinicians in low socioeconomic countries need further
education on appropriate antibiotics to use for GABHS
infection, particularly the proper dose and duration of
those antibiotics and possible repercussions of inappro-
priately prescribed antibiotics. Education should
emphasize the higher prevalence of viral etiology, use of
the McIsaac modified Centor scoring system, and pub-
lished guidelines on treatment of pharyngitis [8,14]. This
is particularly important as India and Pakistan have been
found to be among the initial sites of extremely resistant
organisms such as Escherichia coli and Klebsiella pneu-
monia with the carbapenem-resistance gene blaNDM-1,
[34] which may have resulted from uncontrolled and
excessive use of antibiotics in these countries. Inappro-
priate use of antibiotics in developing regions has conse-
quences for everyone; microbes have no country.
Sensitivity to this issue needs to be renewed by creating
awareness that should be well supported by data.
This study has several limitations. This patient sample
was very small with representation of few selected set-
tings where the influx of patients is from lower- and
middle-class families. A larger sample with patients from
different areas of Karachi in future studies would offer
better-supported conclusions about city-wide prescribing
practices, and about the prevalence of GABHS infection
in adults. The McIsaac–Centor score has been validated
for use in industrialized countries, where prevalence of
rheumatic heart disease is < 1 per 1000 population, com-
pared to >10 per 1000 in Pakistan /Asia [35]. Thus,
using the McIsaac modified score as a routine clinical
tool may also mean that more cases of rheumatic fever
are being prevented, given the higher prevalence of
rheumatic fever in Pakistan compared to the industria-
lized nations.
Conclusions
In Pakistan, antibiotics are prescribed for most cases of
adult pharyngitis when in fact, the majority of the cul-
tures are negative for bacterial infection. Furthermore, it
was alarming for us to discover the high use of second
generation macrolides and cephalosporins rather than
the recommended narrower spectrum agents. McIsaac
modification of Centor score directly related to culture
results. We therefore highly recommend its use to help
family physicians evaluate appropriate use of antibiotics.
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